After the summer romance, the atmosphere is now tense between the European Commission and AstraZeneca (see EUROPE B12547A7). Proof of this is that the third meeting convened, on the evening of Wednesday 27 January, to find a solution to the delivery delays announced by the pharmaceutical company for its candidate vaccine was almost cancelled.
In the meantime, there was a media ping pong match. An interview with AstraZeneca’s CEO Pascal Soriot, published in several European media on...